Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection

This publication has 9 references indexed in Scilit:

• High-performance thin-layer chromatographic determination of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in urine and comparison with high-performance liquid chromatography
  Journal of Chromatography B: Biomedical Sciences and Applications, 1997
• Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, “Eve”) and its metabolites in urine by gas chromatography — mass spectrometry and fluorescence polarization immunoassay
  Journal of Chromatography B: Biomedical Sciences and Applications, 1996
• The demethylenation of methylenedioxymethamphetamine (“ecstasy”) by debrisoquine hydroxylase (CYP2D6)
  Biochemical Pharmacology, 1994
• The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.
  Proceedings of the National Academy of Sciences, 1992
• Synthetische Suchtstoffe der 2. Generation (sog. Designer Drugs) 1. Mitt.: Amphetamine und andere Arylalkanamine
  Pharmazie in unserer Zeit, 1990
• 3,4-Methylenedioxymethamphetamine (MDMA) and Other Amphetamine Derivatives
  Journal of Forensic Sciences, 1988
• 3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain
  European Journal of Pharmacology, 1987
• Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens
  Journal of Psychoactive Drugs, 1986
• Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine)
  Journal of Pharmaceutical Sciences, 1980